TCR2 Therapeutics
675 West Kendall Street
Suite I
Cambridge
Massachusetts
02142
United States
Tel: 617-475-8469
Website: http://www.tcr2.com/
Email: info@tcr2.com
About TCR2 Therapeutics
At TCR2 Therapeutics we have a bold vision – to cure cancer by using our immune system in a more natural way. We have developed a unique proprietary TRuC™ platform based on T cell receptor fusion constructs that have the advantage of employing the full signaling power inherent to a complete T cell receptor (TCR). Our TRuC™ variants can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. We have demonstrated activity against both hematological and solid tumor targets in preclinical models and we believe TRuC™-T cells will serve as the engine for novel therapies which we are quickly advancing towards the clinic.The company was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. We have since assembled a world class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA.
YEAR FOUNDED:
2015
LEADERSHIP:
Founder: Dr. Patrick Baeuerle
CEO: Garry Menzel, PhD and MBA
CSO: Robert Hofmeister, PhD
Acting CSO: John Pallies
Chief IP Counsel: Gregory Sieczkiewicz, PhD and JD
Head of Corporate Development: Helen Ho, PhD
Manager of Human Reources & Office Dynamics: Eva Quinn
TECHNOLOGY:
Please click here for TCR2 Therapeutics's technology.
116 articles about TCR2 Therapeutics
-
Entering the second half of 2022, biopharma and life sciences companies from across the globe strengthen their leadership teams with new additions to the c-suite.
-
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
6/27/2022
TCR2 Therapeutics Inc. announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations.
-
TCR² Therapeutics to Participate in Two Upcoming Conferences in June 2022
6/1/2022
TCR2 Therapeutics Inc. announced that management will participate at two upcoming conferences in June in New York.
-
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2022
6/1/2022
TCR2 Therapeutics Inc. announced that on May 31, 2022, the Compensation Committee of the Board of Directors of TCR2’s approved the grant of inducement stock options covering an aggregate of 19,800 shares of TCR2’s common stock to 3 new non-executive employees.
-
TCR² Therapeutics provided updates regarding the 2022 first quarter financial results and progress made towards regulatory approval for gavo-cel and TC-510.
-
TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/12/2022
TCR² Therapeutics Inc. announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2022
5/2/2022
TCR2 Therapeutics Inc. announced that on April 29, 2022, the Compensation Committee of the Board of Directors of TCR2’s approved the grant of inducement stock options covering an aggregate of 57,200 shares of TCR2’s common stock to 4 new non-executive employees.
-
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2022
4/1/2022
TCR2 Therapeutics Inc. announced that on March 31, 2022, the Compensation Committee of the Board of Directors of TCR2’s approved the grant of inducement stock options covering an aggregate of 73,000 shares of TCR2’s common stock to 9 new non-executive employees.
-
TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update
3/22/2022
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, announced financial results for the fourth quarter ended December 31, 2021 and provided a corporate update.
-
TCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at the American Association of Cancer Research Annual Meeting 2022
3/8/2022
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced it will present a poster at the American Association of Cancer Research (AACR) Annual Meeting 2022 featuring new preclinical data on an allogeneic (off-the-shelf) TRuC-T cells, taking place on April 8-13, 2022 in New Orleans, Louisiana.
-
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 04, 2022
3/4/2022
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, announced that on February 28, 2022, the Compensation Committee of the Board of Directors of TCR2’s approved the grant of inducement stock options covering an aggregate of 15,200 shares of TCR2’s common stock to 3 new non-executive employees.
-
TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference
2/9/2022
TCR 2 Therapeutics Inc. today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 at 1:40PM E.T. using a virtual platform.
-
BioSpace Movers & Shakers, Jan. 14
1/14/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer
1/12/2022
TCR 2 Therapeutics Inc. today announced the appointment of Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer where she will be responsible for supporting a range of activities including commercial strategy, operational planning, corporate partnerships and long-term growth opportunities.
-
TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones
1/10/2022
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, announced its strategic priorities and anticipated milestones for 2022.
-
TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference
1/7/2022
TCR2 Therapeutics Inc. announced that Garry Menzel, President and Chief Executive Officer of TCR2 Therapeutics, will present an update on Company progress at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30AM E.T. using a virtual platform.
-
TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference
1/5/2022
TCR² Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, announced that Garry Menzel, President and Chief Executive Officer of TCR² Therapeutics, will present an update on Company progress at the H.C. Wainwright BioConnect Conference on Monday, January 10th at 7:00AM E.T.
-
TCR² Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies
1/4/2022
TCR2 Therapeutics Inc. (Nasdaq: TCRR), and Arbor Biotechnologies, today announced that the two companies have entered into a strategic research collaboration and non-exclusive license agreement focused on the further development of a defined set of allogeneic TRuC-T cell therapies.
-
TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/10/2021
TCR 2 Therapeutics Inc. today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look.